Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review

Primary sclerosing cholangitis (PSC) is a chronic and progressive immune-mediated cholangiopathy causing biliary tree inflammation and scarring, leading to liver cirrhosis and end-stage liver disease. Diagnosis of PSC is challenging due to its nonspecific symptoms and overlap with other liver diseases. Despite the rising incidence of PSC, there is no proven medical therapy that can alter the natural history of the disease. While liver transplantation (LT) is the most effective approach for managing advanced liver disease caused by PSC, post-transplantation recurrence of PSC remains a challenge. Therefore, ongoing research aims to develop better therapies for PSC, and continued efforts are necessary to improve outcomes for patients with PSC. This article provides an overview of PSC’s pathogenesis, clinical presentation, and management options, including LT trends and future aspects. It also highlights the need for improved therapeutic options and ethical considerations in providing equitable access to LT for patients with PSC. Additionally, the impact of liver transplant on the quality of life and psychological outcomes of patients with PSC is discussed. Ongoing research into PSC’s pathogenesis and post-transplant recurrence is crucial for improved understanding of the disease and more effective treatment options.

[1]  S. Chaudhuri,et al.  Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience , 2023, JGH open : an open access journal of gastroenterology and hepatology.

[2]  D. Ure,et al.  Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH , 2022, Hepatology communications.

[3]  A. Sanyal,et al.  Breakthroughs in therapies for NASH and remaining challenges. , 2022, Journal of hepatology.

[4]  F. Tacke,et al.  Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis , 2022, International journal of molecular sciences.

[5]  F. Nassir.  NAFLD: Mechanisms, Treatments, and Biomarkers , 2022, Biomolecules.

[6]  J. Jelsing,et al.  Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH , 2022, Clinical and translational science.

[7]  Z. Bukumirić,et al.  The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease , 2021, International journal of molecular sciences.

[8]  S. Friedman,et al.  Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies , 2021, Journal of internal medicine.

[9]  T. Rolph,et al.  Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial , 2021, Nature Medicine.

[10]  N. Verma,et al.  Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients. , 2021, Journal of clinical and experimental hepatology.

[11]  K. R,et al.  Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia-A Prospective, Interventional, Pilot Study. , 2021, Journal of clinical and experimental hepatology.

[12]  R. Loomba,et al.  Treatment candidacy for pharmacologic therapies for NASH. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  T. Vanhaecke,et al.  Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists , 2020, Cell Biology and Toxicology.

[14]  F. Tacke,et al.  Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. , 2020, Journal of hepatology.

[15]  M. Gregory,et al.  Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis , 2019, Cells.

[16]  R. Massoumi,et al.  Cyclophilin Inhibitor NV556 Reduces Fibrosis and Hepatocellular Carcinoma Development in Mice With Non-Alcoholic Steatohepatitis , 2019, Front. Pharmacol..

[17]  D. Ure,et al.  A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[18]  T. Vanhaecke,et al.  Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. , 2019, Pharmacological research.

[19]  S. Nada,et al.  Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis , 2019, Inflammation.

[20]  Xiangdong Gao,et al.  A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway , 2018, British journal of pharmacology.

[21]  J. Binet,et al.  Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate. , 2018, Journal of medicinal chemistry.

[22]  S. Park,et al.  LY2405319, an analog of fibroblast growth factor 21 ameliorates α-smooth muscle actin production through inhibition of the succinate—G-protein couple receptor 91 (GPR91) pathway in mice , 2018, PloS one.

[23]  W. Wahli,et al.  Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[24]  H. Jeong,et al.  Correction: Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013) , 2017, Oncotarget.

[25]  I. Leclercq,et al.  The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis , 2017, Hepatology communications.

[26]  C. Mandarim-de-Lacerda,et al.  Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice. , 2015, Life sciences.

[27]  D. Hum,et al.  Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.

[28]  M. Laville,et al.  Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects , 2013, Diabetes Care.

[29]  J. Kuroda,et al.  Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. , 2006, European journal of pharmacology.

[30]  P. J. Larsen,et al.  PPARα/γ ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly , 2003 .

[31]  Kyung Chul Park,et al.  A PPAR Pan Agonist, MHY2013 Alleviates Age-Related Hepatic Lipid Accumulation by Promoting Fatty Acid Oxidation and Suppressing Inflammation. , 2018, Biological & pharmaceutical bulletin.